On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

F. Stephen Hodi

ResearcherPublications, citations & collaboration network

F. Stephen Hodi is a researcher indexed in ScholarIQ from OpenAlex & ORCID.

How many works does F. Stephen Hodi have?

ScholarIQindexed works

F. Stephen Hodi has 1,559 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

How many citations does F. Stephen Hodi have?

ScholarIQcitation count

F. Stephen Hodi has 165,030 citations in the OpenAlex counts ScholarIQ stores.

What is the h-index of F. Stephen Hodi?

ScholarIQh-index

F. Stephen Hodi has an h-index of 157 in OpenAlex.

What is the i10-index of F. Stephen Hodi?

ScholarIQi10-index

F. Stephen Hodi has an i10-index of 507 in OpenAlex.

What is the ORCID of F. Stephen Hodi?

ScholarIQorcid

The ORCID for F. Stephen Hodi is on the source record.

What is the OpenAlex record for F. Stephen Hodi?

ScholarIQopenalex

The OpenAlex for F. Stephen Hodi is on the source record.

What are the most-cited papers on F. Stephen Hodi?

ScholarIQmost cited works
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott Gettinger, David C. Smith, David F. McDermott, John D. Powderly, Richard D. Carvajal, Jeffrey A. Sosman, Michael B. Atkins, Philip D. Leming, David R. Spigel, Scott Antonia, Leora Horn, Charles G. Drake, Drew M. Pardoll, Lieping Chen, William H. Sharfman, Robert A. Anders, Janis M. Taube, Tracee L. McMiller, Haiying Xu, Alan J. Korman, Maria Jure–Kunkel, Shruti Agrawal, D. G. McDonald, Georgia Kollia, Ashok Gupta, Jon M. Wigginton, Mario Sznol
New England Journal of Medicine. 201212,730 CitationsOPEN ACCESS
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin
The Lancet Oncology. 20152,674 Citations
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama, Esra A. Akbay, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana Kulkarni, Mari Kuraguchi, Sangeetha Palakurthi, Peter E. Fecci, Bruce E. Johnson, Pasi A. Jänne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok‐Kin Wong, Peter S. Hammerman
Nature Communications. 20161,586 CitationsOPEN ACCESS
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby‐Arnon, Parin Shah, Michael S. Cuoco, Christopher Rodman, Mei-Ju Su, Johannes C. Melms, Rachel Leeson, Abhay Kanodia, Shaolin Mei, Jia‐Ren Lin, Shu Wang, Bokang Rabasha, David Liu, Gao Zhang, Claire Margolais, Orr Ashenberg, Patrick A. Ott, Elizabeth I. Buchbinder, Rizwan Haq, F. Stephen Hodi, Genevieve M. Boland, Ryan J. Sullivan, Dennie T. Frederick, Benchun Miao, Tabea Moll, Keith T. Flaherty, Meenhard Herlyn, Russell W. Jenkins, Rohit Thummalapalli, Monika S. Kowalczyk, Israel Cañadas, Bastian Schilling, Adam N.R. Cartwright, Adrienne Luoma, Shruti Malu, Patrick Hwu, Chantale Bernatchez, Marie-Andrée Forget, David A. Barbie, Alex K. Shalek, Itay Tirosh, Peter K. Sorger, Kai W. Wucherpfennig, Eliezer M. Van Allen, Dirk Schadendorf, Bruce E. Johnson, Asaf Rotem, Orit Rozenblatt–Rosen, Levi A. Garraway, Charles H. Yoon, Benjamin Izar, Aviv Regev
Cell. 20181,476 CitationsOPEN ACCESS
Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
Scott Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott Antonia, Naiyer A. Rizvi, John D. Powderly, Rebecca S. Heist, Richard D. Carvajal, David M. Jackman, Lecia V. Sequist, David C. Smith, Philip D. Leming, David P. Carbone, Mary Pinder-Schenck, Suzanne L. Topalian, F. Stephen Hodi, Jeffrey A. Sosman, Mario Sznol, David F. McDermott, Drew M. Pardoll, Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Matthew D. Hellmann, Georgia Kollia, Ashok Gupta, Julie R. Brahmer
Journal of Clinical Oncology. 20151,197 CitationsOPEN ACCESS

Related on ScholarIQ

470M+ articles · free account